Related Experiment Videos
Successful treatment of refractory neuroSjogren with Rituximab
B Yamout1, T El-Hajj, W Barada
1Department of Internal Medicine, Faculty of Medicine, American University of Beirut, Beirut, Lebanon. yamoutba@idm.net.lb
Abstract:
We report a 47-year-old female with Sjogren's syndrome (SS) and severe weakness in her lower extremities refractory to cyclophosphamide therapy, who was treated with the monoclonal anti CD-20 antibody rituximab at a weekly dose of 375 mg/m2 for four consecutive weeks. Patient responded within few days of the first dose and her motor power in the lower extremities started to improve gradually along with progressive resolution of the paresthesias and dysesthesias. The improvement was sustained and progressive and eight months after the last dose, she was able to walk for 60 meters without aid or rest. Rituximab may be considered as an effective and promising novel therapy in SS patients with neurological involvement.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Respiratory Syncytial Virus Disease
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF